Free Trial
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

$520.93
+9.63 (+1.88%)
(As of 12:31 PM ET)

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Key Stats

Today's Range
$519.01
$530.60
50-Day Range
$455.08
$512.27
52-Week Range
$372.50
$583.39
Volume
97,574 shs
Average Volume
472,176 shs
Market Capitalization
$43.02 billion
P/E Ratio
50.43
Dividend Yield
N/A
Price Target
$582.25
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 91st Percentile

IDEXX Laboratories scored higher than 91% of companies evaluated by MarketBeat, and ranked 113th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEXX Laboratories has only been the subject of 3 research reports in the past 90 days.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 17.51% in the coming year, from $10.45 to $12.28 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 50.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.52.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 50.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.59.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 4.17. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 29.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    2.86% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 3.32%, indicating that investor sentiment is improving.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.86% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 3.32%, indicating that investor sentiment is improving.
  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for IDEXX Laboratories this week, compared to 9 articles on an average week.
  • Search Interest

    Only 4 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.11% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.

IDXX Stock News Headlines

Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
IDEXX Laboratories Inc (IX1.BE)
IDEXX Laboratories, Inc. (IX1.DE)
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $555.05 on January 1st, 2024. Since then, IDXX shares have decreased by 6.3% and is now trading at $520.16.
View the best growth stocks for 2024 here
.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Tuesday, August, 6th. The company reported $2.44 earnings per share for the quarter, missing analysts' consensus estimates of $2.88 by $0.44. The firm's revenue was up 6.4% compared to the same quarter last year.
Read the conference call transcript
.

IDEXX Laboratories' top institutional shareholders include Blair William & Co. IL (1.42%), Legal & General Group Plc (0.94%), Principal Financial Group Inc. (0.91%) and Bank of New York Mellon Corp (0.75%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, James F Polewaczyk, Kathy V Turner, George Fennell, Michael Lane, Daniel M Junius, M Anne Szostak, Sophie V Vandebroek and Bruce L Claflin.
View institutional ownership trends
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA) and Alibaba Group (BABA).

Company Calendar

Last Earnings
8/06/2024
Today
9/19/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
11,000
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$582.25
High Stock Price Target
$650.00
Low Stock Price Target
$510.00
Potential Upside/Downside
+13.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$845.04 million
Pretax Margin
28.06%

Debt

Sales & Book Value

Annual Sales
$3.78 billion
Cash Flow
$12.05 per share
Book Value
$17.88 per share

Miscellaneous

Free Float
80,844,000
Market Cap
$42.23 billion
Optionable
Optionable
Beta
1.33

Social Links

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 9, 2024. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDEXX Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • Strong Consensus Rating: IDEXX Laboratories currently has a consensus rating of "Moderate Buy," indicating positive sentiment from analysts.
  • Consistent Revenue Growth: IDEXX Laboratories reported a revenue increase of 6.4% in the latest quarter, showcasing a healthy growth trajectory.
  • Healthy Return on Equity: With a return on equity of 63.66%, IDEXX Laboratories demonstrates efficient utilization of shareholder equity.
  • Market Cap and Stability: IDEXX Laboratories has a market cap of $40.65 billion, reflecting its size and stability in the market.
  • Attractive Stock Price: IDEXX Laboratories stock is currently trading at $492.26, showing potential for value appreciation.

IDEXX Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • Earnings Miss: IDEXX Laboratories reported earnings per share of $2.44 for the latest quarter, falling short of analysts' consensus estimates.
  • Decrease in Stock Price: IDEXX Laboratories stock traded down 0.6% recently, indicating short-term downward pressure.
  • Insider Selling: Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock, potentially signaling lack of confidence from insiders.
  • Debt-to-Equity Ratio: IDEXX Laboratories has a debt-to-equity ratio of 0.40, which may raise concerns about its financial leverage.
  • Lower Analyst Estimates: Analysts forecast IDEXX Laboratories to post 11 EPS for the current year, potentially lower than previous expectations.

This page (NASDAQ:IDXX) was last updated on 9/19/2024 by MarketBeat.com Staff
From Our Partners